All In Biotech

NDA 208956 · Azurity

Triptodur Kit

Triptorelin Pamoate · Intramuscular

Orphan

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jun 29, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

246

82 Phase 3, 36 recruiting

FAERS reports

3,354

2,156 serious, 198 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 14, 2025.

TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). TRIPTODUR is a gonadotropin releasing hormone (GnRH) agonist indicated for the treatment of pediatric patients 2 years and older with central precocious puberty. ( 1 )

Mechanism: Triptorelin is a GnRH agonist.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 29, 2017 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLabelLetterReview
1 products under this application
  • TRIPTODUR KIT · TRIPTORELIN PAMOATE EQ 22.5MG BASE/VIAL · FOR SUSPENSION, EXTENDED RELEASE, INTRAMUSCULAR · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Triptorelin Pamoate" as an intervention, any sponsor and status, largest first.

All 246 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use289
  • needle issue199
  • disease progression133
  • product dose omission issue125
  • drug ineffective118
  • headache114
  • injection site pain104
  • weight increased104
  • ovarian hyperstimulation syndrome101
  • vaginal haemorrhage95
  • syringe issue90
  • asthenia88

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
200510
20063
200713
200814
200910
201024
201119
201219
201310
201429
201533
201619
201751
2018180
2019459
2020378
2021420
2022309
2023342
2024331
2025439
2026238

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 9 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.